Knockout animals manifesting hyperlipidemia

Details Knockout animals manifesting hyperlipidemia Knockout animals manifesting hyperlipidemia

2006-02-03

2008-07-22

Woitach, Joesph (Department: 1633)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S003000, C800S006000, C800S008000, C800S021000, C435S325000

Reexamination Certificate

active

07402730

ABSTRACT:
Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal antibodies against GHP1.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4631211 (1986-12-01), Houghten
patent: 4689405 (1987-08-01), Frank et al.
patent: 4713326 (1987-12-01), Dattagupta et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5487992 (1996-01-01), Capecchi et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5700637 (1997-12-01), Southern
patent: 5744305 (1998-04-01), Fodor et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5869619 (1999-02-01), Studnicka
patent: 5877397 (1999-03-01), Lonbert et al.
patent: 5968502 (1999-10-01), Treco et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6524818 (2003-02-01), Harrington et al.
patent: 0154316 (1985-09-01), None
patent: 0401384 (1990-12-01), None
patent: WO 88/01649 (1988-03-01), None
patent: WO 92/16221 (1992-10-01), None
patent: WO 95/13312 (1995-05-01), None
patent: WO 95/34326 (1995-12-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/19459 (1996-06-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 02/070669 (2002-09-01), None
Jiao et al., 1990, Metabolism 39:155-60.
Holschneider et al., 2001, Int. J. Devl. Neuroscience 18:615-618.
Gerlai et al.,1996, Trends in Neuro Sciences 19:177-181.
Ioka et. al., 2003, J Biol. Chem. 278:7344-7349.
Bitter et al, 1987, “Expression and Secretion Vectors for Yeast”, Methods in Enzymology 153:516-544.
Blake et al, 1996, “Metal Binding Properties of a Monoclonal Antibody Directed toward Metal-Chelate Complexes”, Journal of Biological Chemistry 271:27677-27685.
Boder et al, 2000, “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity”, PNAS 97:10701-10705.
Boder et al, 1997, “Yeast surface display for screening combinatorial polypeptide libraries”, Nature Biotechnology 15:553-557.
Borrebaeck et al, 1988, “Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes”, Proc. Natl. Acad. Sci. USA 85:3995-3999.
Bowie et al., 1991, “A Method to Identify Protein Sequences That Fold into a Known Three-Dimensional Structure”, Science 253:164-170.
Brekke et al., 2003, “Therapeutic antibodies for human diseases at the dawn of the twenty-first century”, Nature 2:52-62I.
Brenner et al., 1997, “Population statistics of protein structures: lessons from structural classifications”, Current Opinion in Structural Biology 7:369-376.
Brommage, 2003, “Validation and calibration of DEXA body composition in mice”, Am J Physiol Endocrinol Metab 285:E454-E459.
Carpenter et al., 1971, “Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization”, Toxicology and Applied Pharmacology 18:35-40.
Chavez et al., 2005, “Acid Ceramidasae Overexpression Prevents the Inhibitory Effects of Saturated Fatty Acids on Insulin Signaling”, Journal of Biological Chemistry 280:20148-20153.
Chothia et al., 1989, “Conformations on immunoglobulin hypervariable regions”, Nature 342::877-883.
Chothia et al., 1987, “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol. 196:901-917.
Chou et al., 1979, “Prediction of β-Turns”, Biophys. J. Biophysical Society 26:367-384.
Chou et al., 1978, “Empirical Predictions of Protein Conformation”, Ann. Res. Biochem. 47:251-276.
Chou et al., 1974, “Conformational Parametaers for Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated from Proteins”, Biochemistry 13:211-222.
Chou et al., 1974, “Prediction of Protein Conformation”, Biochemistry 13:222-244.
Chou et al, 1978, “Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence”, Adv. Enzymol Relat Area Mol Biol 147:45-148.
Clackson et al, 1991, “Making antibody fragments using phage display libraries”, Nature 352:624-628.
Colbere-Garapin et al, 1981, “A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells”, J. Mol. Biol. 150:1-14.
Corrigan et al, 1982, “A Basic microcomputer program for plotting the secondary structure of proteins”, Computer Programs in Biomedicine 15:163-168.
Crameri et al., 1996, “Construction and evolution of antibody-phage libraries by DNA shuffling”, Nature Medicine 2:100-102.
Drake et al, 2004, “Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods”, Analytical Biochemistry 328:35-43.
Fishwild et al., 1996, “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice”, Nature Biotechnology 14:845-851.
Foote et al, 2000, “Breaking the affinity ceiling for antibodies and T cell receptors”, PNAS 97:10679-10681.
Goldberg et al., 1993, “Methods for measurement of antibody/antigen affinity based on ELISA and RIA”, Current Biology 278-280.
Gordon, 1989, “Transgenic Animals”, International Review of Cytology, 115:171-229.
Green, 1999, “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies”, Journal of Immunological Methods 231:11-23.
Gribskov et al., 1987, “Profile analysis: Detection of distantly related proteins”, Proc. Natl. Acad. Sci. USA 84:4355-4358.
Gribskov et al., 1990, “Profile Analysis”, Methods in Enzymology 183:146-159.
Gu et al, 1994, “Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting”, Science 265:103-106.
Hanes et al., 1998, “Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries”, Proc. Natl. Acad. Sci. USA 95:14130-14135.
Hoogenboom, 2002, “Overview of Antibody Phage-Display Technology and its Applications”, Methods in Molecular Biology 178:1-37.
Hopp et al., 1981, “Prediction of protein antigenic determinants from amino acid sequences”, Proc. Natl. Acad. Sci. USA 78:3824-3828.
Hudson et al., 2003, “Engineered antibodies”, Nature Medicine 9:129-134.
Inouye et al., 1985, “Up-promoter mutations in the Ipp gene ofEscherichia coli”, Nucleic Acids Research 13(9):3101-3110.
Ioka et al., 2003, “Expression Cloning and Characterization of a Novel Glycosylphosphatidylinositol-anchored High Density Lipoprotein-binding Proetin, GPI-HBI1”, Journal of Biological Chemistry 278:7344-7349.
Irwin, 1968, “Comprehensive Observational Assessment: Ia. A Systematic, Quantitative Procedure for Assessing the Behavioral and Physiologic State of the Mouse”, Psychopharmacologia 13:222-257.
Jakobovits, 1995, “Production of fully human antibodies by transgenic mice”, Current Opinion in Biotechnology 6:561-566.
Jakobovits et al., 1993, “Germ-line transmission and expression of a human-derived yeast artificial chromosome

Affiliated with

Also associated with

Rating

Knockout animals manifesting hyperlipidemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Knockout animals manifesting hyperlipidemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Knockout animals manifesting hyperlipidemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3968442